Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (231-240 of 467) with videos related to

Pageof 47
Sort By:
Breast Cancer Research and Treatment|March 6, 2010
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerMichael Knauer, Stella Mook, Emiel J T Rutgers, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Breast cancer risk SNPs converge on estrogen receptor binding sites commonly shared between breast tumors to locally alter estrogen signalling outputStacey Ep Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Toxicology Mechanisms and Methods|May 17, 2018
Evaluating mice lacking serum carboxylesterase as a behavioral model for nerve agent intoxicationEmily N Dunn, Teresa M Ferrara-Bowens, Mark E Chachich, et al.
Lancet (London, England)|April 20, 2002
Molecular characterisation of soft tissue tumours: a gene expression studyTorsten O Nielsen, Rob B West, Sabine C Linn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 20, 2015
Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide studyA Kuijer, A C M van Bommel, C A Drukker, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2017
Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumorsMarjolein Droog, Ekaterina Nevedomskaya, Gwen M Dackus, et al.
British Journal of Cancer|February 6, 2022
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patientsLeonora W de Boo, Katarzyna Jóźwiak, Heikki Joensuu, et al.
Breast Cancer Research : BCR|June 3, 2014
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyMarieke A Vollebergh, Esther H Lips, Petra M Nederlof, et al.
Molecular Cancer Research : MCR|April 5, 2020
The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast CancersIrida Kastrati, Stacey E P Joosten, Svetlana E Semina, et al.
Breast Cancer Research and Treatment|June 6, 2013
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatmentK Beelen, M Opdam, T M Severson, et al.
Pageof 47

Showing results (231-240 of 467) with videos related to

Sort By:
Pageof 47
Breast Cancer Research and Treatment|March 6, 2010
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerMichael Knauer, Stella Mook, Emiel J T Rutgers, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Breast cancer risk SNPs converge on estrogen receptor binding sites commonly shared between breast tumors to locally alter estrogen signalling outputStacey Ep Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Toxicology Mechanisms and Methods|May 17, 2018
Evaluating mice lacking serum carboxylesterase as a behavioral model for nerve agent intoxicationEmily N Dunn, Teresa M Ferrara-Bowens, Mark E Chachich, et al.
Lancet (London, England)|April 20, 2002
Molecular characterisation of soft tissue tumours: a gene expression studyTorsten O Nielsen, Rob B West, Sabine C Linn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 20, 2015
Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide studyA Kuijer, A C M van Bommel, C A Drukker, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2017
Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumorsMarjolein Droog, Ekaterina Nevedomskaya, Gwen M Dackus, et al.
British Journal of Cancer|February 6, 2022
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patientsLeonora W de Boo, Katarzyna Jóźwiak, Heikki Joensuu, et al.
Breast Cancer Research : BCR|June 3, 2014
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyMarieke A Vollebergh, Esther H Lips, Petra M Nederlof, et al.
Molecular Cancer Research : MCR|April 5, 2020
The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast CancersIrida Kastrati, Stacey E P Joosten, Svetlana E Semina, et al.
Breast Cancer Research and Treatment|June 6, 2013
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatmentK Beelen, M Opdam, T M Severson, et al.
Pageof 47